Featured Research

from universities, journals, and other organizations

Hypertonic Resuscitation May Help Victims Of Blunt Trauma

Date:
June 30, 2003
Source:
University Of Washington
Summary:
Hypertonic resuscitation – a concentrated intravenous (IV) dose of saline and dextran, a sugar solution – has the potential to help survivors of blunt trauma by improving blood flow and delivery of oxygen to the injured brain while decreasing high pressure in the brain, a common problem for patients with brain injury. This therapy is now being tested in a research study by University of Washington (UW) physicians based at Harborview Medical Center.

Hypertonic resuscitation – a concentrated intravenous (IV) dose of saline and dextran, a sugar solution – has the potential to help survivors of blunt trauma by improving blood flow and delivery of oxygen to the injured brain while decreasing high pressure in the brain, a common problem for patients with brain injury. This therapy is now being tested in a research study by University of Washington (UW) physicians based at Harborview Medical Center.

Related Articles


“Trauma is the leading cause of death for Americans between 1 and 44 years of age,” says Dr. Eileen Bulger, a UW assistant professor of surgery and principal investigator for the study. “Of the trauma patients we treat at Harborview, 80 percent are victims of blunt trauma - drivers and passengers in motor vehicle crashes, injured motorcyclists, pedestrians and bicyclists struck by cars, and victims of falls and assaults with blunt objects.”

Trauma care begins in the field, Bulger explains, with paramedics and flight nurses providing airway management, spinal immobilization and IV fluids. Given to help replace lost blood and support blood flow to vital organs, IV fluids are especially important for trauma patients who have suffered brain injuries. Current pre-hospital treatment includes two liters of an IV saline solution having a similar concentration to human plasma.

The experimental hypertonic saline/dextran (HSD) solution is more concentrated than the current treatment and may offer potential benefits to victims of blunt trauma, Bulger says, including more rapid improvement of blood pressure, improved blood flow to the injured brain while decreasing the high pressure in the brain, and an altered immune system response which may decrease the risk of infection and acute respiratory distress syndrome.

HSD is already approved for use in 14 countries, including the United Kingdom, France, Germany, Sweden, Norway and Denmark. It has been the subject of eight previous clinical trials in the U.S., all of which showed improved survival with HSD, but these studies had an insufficient number of subjects or involved patients with primarily penetrating trauma.

The Harborview study, which is funded by the National Institute of Health, will enroll 400 patients. Half will receive traditional resuscitation and half will receive HSD. All other aspects of medical and surgical care will be the same for both groups.

Because HSD must be administered shortly after injury, it will be difficult to obtain informed consent from patients, who may be unconscious, or their family members. The Food and Drug Administration and the UW’s Human Subjects Review Committee has given the researchers permission to do this study and enroll patients without their consent due to the emergency nature of their illness. All participants (or family members) will be asked to give their informed consent to continue in the study once it is possible to do so. A recently completed community survey of residents from King County and the surrounding region suggest support for the study with 75% of respondents indicating that they would consent to receive the study fluid if injured and 77% agreeing that the waiver of informed consent is justified.

Potential side effects of HSD include possible allergic reaction to dextran, seizures due to very high salt levels in the blood, an rapid increase in blood pressure leading to more bleeding. None of these side effects have been seen in previous clinical trials.

Harborview Medical Center and the University of Washington welcome public comment on the HSD study. Further information can be found on the study’s web site: http://www.washington.edu/medicine/hmc/overview/studies/esd.htmlor by leaving a message at 1-800-506-1309 or 206-341-4721.


Story Source:

The above story is based on materials provided by University Of Washington. Note: Materials may be edited for content and length.


Cite This Page:

University Of Washington. "Hypertonic Resuscitation May Help Victims Of Blunt Trauma." ScienceDaily. ScienceDaily, 30 June 2003. <www.sciencedaily.com/releases/2003/06/030627000429.htm>.
University Of Washington. (2003, June 30). Hypertonic Resuscitation May Help Victims Of Blunt Trauma. ScienceDaily. Retrieved November 28, 2014 from www.sciencedaily.com/releases/2003/06/030627000429.htm
University Of Washington. "Hypertonic Resuscitation May Help Victims Of Blunt Trauma." ScienceDaily. www.sciencedaily.com/releases/2003/06/030627000429.htm (accessed November 28, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, November 28, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com
Experimental Ebola Vaccine Shows Promise In Human Trial

Experimental Ebola Vaccine Shows Promise In Human Trial

Newsy (Nov. 27, 2014) — A recent test of a prototype Ebola vaccine generated an immune response to the disease in subjects. Video provided by Newsy
Powered by NewsLook.com
Pet Dogs to Be Used in Anti-Ageing Trial

Pet Dogs to Be Used in Anti-Ageing Trial

Reuters - Innovations Video Online (Nov. 26, 2014) — Researchers in the United States are preparing to discover whether a drug commonly used in human organ transplants can extend the lifespan and health quality of pet dogs. Video provided by Reuters
Powered by NewsLook.com
Today's Prostheses Are More Capable Than Ever

Today's Prostheses Are More Capable Than Ever

Newsy (Nov. 26, 2014) — Advances in prosthetics are making replacement body parts stronger and more lifelike than they’ve ever been. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins